科技自主创新结硕果！以岭药业研发“大爆发”，年均一款新药进医保目录

Core Viewpoint - Yiling Pharmaceutical has successfully included its innovative traditional Chinese medicine, Qifang Nasal Tablets, in the National Medical Insurance Directory, marking a significant recognition of the company's innovation value and responsibility in the healthcare sector [1] Group 1: Product Development and Approval - Qifang Nasal Tablets, approved for treating allergic rhinitis, is the fifth innovative traditional Chinese medicine from Yiling Pharmaceutical to be included in the National Medical Insurance Directory [1] - The drug has shown significant efficacy in clinical trials, with a total effective rate of 74.71% and a patient satisfaction improvement rate of 89% [2] - Yiling Pharmaceutical has a strong pipeline, with two new traditional Chinese medicines and one classic formula currently in the new drug application process [7] Group 2: Research and Development Investment - Yiling Pharmaceutical maintains a high level of R&D investment, with total expenditures of 895 million, 935 million, and 908 million yuan from 2022 to 2024, consistently ranking among the top in the traditional Chinese medicine industry [3] - The company has successfully launched five innovative traditional Chinese medicines in the past five years, all of which are included in the medical insurance directory [3] Group 3: Market Performance and Growth - The company has established a solid revenue base with major products like Tongxinluo, Rensong Yangxin, and Qilichangxin, each generating over 1 billion yuan in annual sales [6] - There is a notable rise in revenue contribution from secondary products, indicating a shift in the company's growth dynamics [5][6] - Yiling Pharmaceutical has maintained a steady rhythm of R&D, aiming to introduce 1-2 new products into clinical research and approval each year [6]